- Home
- NFJ vs SYRE Comparison
NFJ vs SYRE Comparison
Compare NFJ & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- SYRE
- Stock Information
- Founded
- NFJ 2005
- SYRE 2013
- Country
- NFJ United States
- SYRE United States
- Employees
- NFJ N/A
- SYRE 60
- Industry
- NFJ Finance: Consumer Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- SYRE Health Care
- Exchange
- NFJ Nasdaq
- SYRE Nasdaq
- Market Cap
- NFJ 1.2B
- SYRE 897.9M
- IPO Year
- NFJ N/A
- SYRE 2016
- Fundamental
- Price
- NFJ $12.12
- SYRE $15.30
- Analyst Decision
- NFJ
- SYRE Strong Buy
- Analyst Count
- NFJ 0
- SYRE 8
- Target Price
- NFJ N/A
- SYRE $51.50
- AVG Volume (30 Days)
- NFJ 223.5K
- SYRE 651.5K
- Earning Date
- NFJ 01-01-0001
- SYRE 05-08-2025
- Dividend Yield
- NFJ 9.01%
- SYRE N/A
- EPS Growth
- NFJ N/A
- SYRE N/A
- EPS
- NFJ N/A
- SYRE N/A
- Revenue
- NFJ N/A
- SYRE N/A
- Revenue This Year
- NFJ N/A
- SYRE N/A
- Revenue Next Year
- NFJ N/A
- SYRE N/A
- P/E Ratio
- NFJ N/A
- SYRE N/A
- Revenue Growth
- NFJ N/A
- SYRE N/A
- 52 Week Low
- NFJ $10.45
- SYRE $15.26
- 52 Week High
- NFJ $12.86
- SYRE $40.84
- Technical
- Relative Strength Index (RSI)
- NFJ 39.22
- SYRE 32.29
- Support Level
- NFJ $12.07
- SYRE $16.71
- Resistance Level
- NFJ $12.26
- SYRE $18.28
- Average True Range (ATR)
- NFJ 0.15
- SYRE 1.21
- MACD
- NFJ 0.01
- SYRE -0.13
- Stochastic Oscillator
- NFJ 61.36
- SYRE 1.29
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. Its primary investment objective is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.